Unveiling the Secret Behind a Groundbreaking Antibiotic's Effectiveness Against Multidrug-Resistant Tuberculosis

**Rutgers Health researchers** have uncovered essential insights into the effectiveness of **bedaquiline**, a relatively new antibiotic, against multidrug-resistant **tuberculosis (TB)**. The study reveals that deficiencies in the enzyme catalase-peroxidase, encoded by the katG gene, play a crucial role in making resistant TB strains vulnerable to bedaquiline. **Published in Nature Communications**, this research highlights that these deficiencies increase the accumulation of reactive oxygen species and DNA damage, while altering transcriptional programs that regulate bacterial biology. Bedaquiline, which was approved in 2012 by the **FDA**, is the first new TB drug in over 40 years, offering hope in combatting one of the world's deadliest infectious diseases. The study suggests that understanding these vulnerabilities could lead to more effective treatments, potentially reducing doses or shortening treatment times. Additionally, the research opens doors for developing new drugs or combinations that enhance the efficacy of existing ones, such as **isoniazid**. Rutgers' team, led by Jason Yang, aims to leverage machine learning and synthetic biology tools to further explore personalized medicine approaches for TB, potentially tailoring treatments to individual strains. The findings could also help repurpose existing antibiotics like trimethoprim and sulfamethoxazole to tackle drug-resistant TB, marking significant strides in addressing global antibiotic resistance challenges.